Xenetic Biosciences with ticker code (XBIO) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 5 and 2.5 with the average target price sitting at 3.75. Given that the stocks previous close was at 3.14 this is indicating there is a potential upside of 19.4%. There is a 50 day moving average of 2.81 while the 200 day moving average is 1.56. The market capitalisation for the company is $24m. Company Website: http://www.xeneticbio.com
Xenetic Biosciences, a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences is headquartered in Framingham, Massachusetts.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
